Scholarlink

Introduction <p>The severe acute respiratory syndrome coronavirus&#xa0;2 (SARS-CoV-2) pandemic significantly changed the development and use of infectious disease diagnostics, emphasizing the need for rapid implementation, access equity, and revealing challenges in evaluation and licensing from unclear guidelines.</p> Methods <p>An international expert panel was convened by Roche Diagnostics, Fraunhofer Institute for Translational Medicine and Pharmacology (Immunology, Infection and Pandemic Research division), and Ludwig Maximilians University to address these challenges. The panel aimed to develop parameters for designing minimal viable products and consequence-centered diagnostic strategies, focusing on the broader implications of test results for public health interventions and disease control rather than individual test performance.</p> Results <p>Key findings included the need to tailor target product profiles to outbreak scenarios, considering socioeconomic factors and outbreak phases. Prioritizing rapid, cost-effective, and widely accessible tests, even at the expense of lower sensitivity was highlighted. Using such tools was effective during the SARS-CoV-2 pandemic because they were wider-reaching and identified more cases, especially in low-/middle-income countries where highly sensitive molecular tests had limited availability.</p> Conclusion <p>Modeling different testing strategies allows outbreak control programs to quantify the impact of trade-offs between accessibility, affordability, and speed of diagnosis in different outbreak settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lessons Learned: Defining the Right Specifications for Diagnostics in Outbreak Situations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Markus Beutler,
  • Pablo Bonvehí,
  • May Chu,
  • Veasna Duong,
  • Rosanna W. Peeling,
  • Jonas Schmidt-Chanasit,
  • Simon Jochum,
  • Christoph Sticha-Kaiser,
  • Noemi Castelletti,
  • Matthias Strobl,
  • Andreas Wieser

摘要

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic significantly changed the development and use of infectious disease diagnostics, emphasizing the need for rapid implementation, access equity, and revealing challenges in evaluation and licensing from unclear guidelines.

Methods

An international expert panel was convened by Roche Diagnostics, Fraunhofer Institute for Translational Medicine and Pharmacology (Immunology, Infection and Pandemic Research division), and Ludwig Maximilians University to address these challenges. The panel aimed to develop parameters for designing minimal viable products and consequence-centered diagnostic strategies, focusing on the broader implications of test results for public health interventions and disease control rather than individual test performance.

Results

Key findings included the need to tailor target product profiles to outbreak scenarios, considering socioeconomic factors and outbreak phases. Prioritizing rapid, cost-effective, and widely accessible tests, even at the expense of lower sensitivity was highlighted. Using such tools was effective during the SARS-CoV-2 pandemic because they were wider-reaching and identified more cases, especially in low-/middle-income countries where highly sensitive molecular tests had limited availability.

Conclusion

Modeling different testing strategies allows outbreak control programs to quantify the impact of trade-offs between accessibility, affordability, and speed of diagnosis in different outbreak settings.